They might be on to something.

By Diana Novak Jones Dec 12 (Reuters) - A California jury on Friday awarded $40 million to two women who said Johnson & Johnson’s baby powder was to blame for their ovarian cancer. The jury in Los Ang ...

The trial featured two California women who developed ovarian cancer after decades of using the company's talc-based baby powder products. The award to plaintiffs Monica Kent and Deborah Schultz, and ...

Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted ...

Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim ...

Johnson & Johnson MedTech (NYSE:JNJ) is enacting an organizational restructuring, changing the way its business units operate ...

A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause ...

Johnson & Johnson’s failed attempts to resolve a mountain of talcum powder lawsuits through class-action bankruptcy settlements have left the company with the daunting prospect of litigating cases ...

Johnson & Johnson stock nears $200 after rally. Find out why analysts maintain a Hold rating on JNJ stock and a $220 price ...

Johnson & Johnson was ordered to pay $966 million to the family of a woman who alleged the New Brunswick-headquartered health giant’s talcum-based baby powder gave her a fatal cancer. Following a ...

The New York Jets have agreed to a multi-year sponsorship with Johnson & Johnson to promote better health to Jets fans, making them the team's Official Medical Innovation Sponsor. Johnson & Johnson ...